Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (11): 1170-1175.doi: 10.11958/20230126
• Cell and Molecular Biology • Previous Articles Next Articles
LIU Huimin(), XU Xuanxuan, WANG Yuanli, XIONG Tao, TANG Yuanyan△(
)
Received:
2023-02-03
Revised:
2023-04-07
Published:
2023-11-15
Online:
2023-11-07
Contact:
△E-mail:LIU Huimin, XU Xuanxuan, WANG Yuanli, XIONG Tao, TANG Yuanyan. Impacts of CircBACH1 on proliferation, apoptosis and chemosensitivity of multiple myeloma cells by regulating miR-140-5p /MDM2 axis[J]. Tianjin Medical Journal, 2023, 51(11): 1170-1175.
CLC Number:
基因名称 | 引物序列(5′→3′) | 产物大小/bp |
---|---|---|
CircBACH1 | 上游:GCTGTCGCAAGAGAAAACTTGA | 198 |
下游:AAACTCCACACATTTGCACACT | ||
MDM2 | 上游:CAGTAGCAGTGAATCTACAGGGA | 139 |
下游:CTGATCCAACCAATCACCTGAAT | ||
GAPDH | 上游:CAGAACATCATCCCTGCCTCTAC | 216 |
下游:TTGAAGTCAGAGGAGACCACCTG | ||
miR-140-5p | 上游:CAGTGGTTTTACCCTA | 142 |
下游:GTGCAGGGTCCGAGGT | ||
U6 | 上游:CTCGCTTCGGCAGCACA | 89 |
下游:AACGCTTCACGAATTTGCG |
Tab.1 qRT-PCR primers
基因名称 | 引物序列(5′→3′) | 产物大小/bp |
---|---|---|
CircBACH1 | 上游:GCTGTCGCAAGAGAAAACTTGA | 198 |
下游:AAACTCCACACATTTGCACACT | ||
MDM2 | 上游:CAGTAGCAGTGAATCTACAGGGA | 139 |
下游:CTGATCCAACCAATCACCTGAAT | ||
GAPDH | 上游:CAGAACATCATCCCTGCCTCTAC | 216 |
下游:TTGAAGTCAGAGGAGACCACCTG | ||
miR-140-5p | 上游:CAGTGGTTTTACCCTA | 142 |
下游:GTGCAGGGTCCGAGGT | ||
U6 | 上游:CTCGCTTCGGCAGCACA | 89 |
下游:AACGCTTCACGAATTTGCG |
组别 | CircBACH1 | miR-140-5p | MDM2 |
---|---|---|---|
正常对照组 | 1.02±0.07 | 0.98±0.06 | 0.96±0.05 |
MM组 | 1.97±0.15a | 0.37±0.03a | 1.61±0.11a |
U266细胞 | 2.01±0.12a | 0.34±0.03a | 1.68±0.10a |
F | 405.689** | 1304.333** | 346.024** |
Tab.2 Comparison of mRNA expression levels of CircBACH1, miR-140-5p and MDM2 between three groups
组别 | CircBACH1 | miR-140-5p | MDM2 |
---|---|---|---|
正常对照组 | 1.02±0.07 | 0.98±0.06 | 0.96±0.05 |
MM组 | 1.97±0.15a | 0.37±0.03a | 1.61±0.11a |
U266细胞 | 2.01±0.12a | 0.34±0.03a | 1.68±0.10a |
F | 405.689** | 1304.333** | 346.024** |
组别 | CircBACH1 | miR-140-5p | MDM2 |
---|---|---|---|
Control组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
si-NC组 | 0.98±0.05 | 1.02±0.05 | 1.01±0.06 |
si-CircBACH1组 | 0.46±0.03ab | 1.93±0.13ab | 0.39±0.02ab |
si-CircBACH1+anti- miR-NC组 | 0.44±0.02 | 1.91±0.14 | 0.41±0.03 |
si-CircBACH1+anti- miR-140-5p组 | 0.46±0.03 | 1.32±0.08c | 0.77±0.05c |
F | 276.128** | 69.823** | 187.459** |
Tab.3 Comparison of mRNA expression levels of CircBACH1, miR-140-5p and MDM2 between five groups of cells
组别 | CircBACH1 | miR-140-5p | MDM2 |
---|---|---|---|
Control组 | 1.00±0.00 | 1.00±0.00 | 1.00±0.00 |
si-NC组 | 0.98±0.05 | 1.02±0.05 | 1.01±0.06 |
si-CircBACH1组 | 0.46±0.03ab | 1.93±0.13ab | 0.39±0.02ab |
si-CircBACH1+anti- miR-NC组 | 0.44±0.02 | 1.91±0.14 | 0.41±0.03 |
si-CircBACH1+anti- miR-140-5p组 | 0.46±0.03 | 1.32±0.08c | 0.77±0.05c |
F | 276.128** | 69.823** | 187.459** |
组别 | Bcl-2 | Bax | cleaved caspase-3 |
---|---|---|---|
Control组 | 1.02±0.05 | 0.97±0.04 | 0.92±0.04 |
si-NC组 | 1.01±0.05 | 0.95±0.04 | 0.93±0.05 |
si-CircBACH1组 | 0.41±0.02ab | 1.52±0.06ab | 1.44±0.06ab |
si-CircBACH1+anti- miR-NC组 | 0.42±0.02 | 1.51±0.06 | 1.45±0.07 |
si-CircBACH1+anti- miR-140-5p组 | 0.72±0.04c | 1.21±0.05c | 1.17±0.05c |
F | 182.493 | 89.791 | 67.222 |
Tab.4 Comparison of expression levels of Bcl-2, Bax, and cleaved caspase-3 between five groups of cells
组别 | Bcl-2 | Bax | cleaved caspase-3 |
---|---|---|---|
Control组 | 1.02±0.05 | 0.97±0.04 | 0.92±0.04 |
si-NC组 | 1.01±0.05 | 0.95±0.04 | 0.93±0.05 |
si-CircBACH1组 | 0.41±0.02ab | 1.52±0.06ab | 1.44±0.06ab |
si-CircBACH1+anti- miR-NC组 | 0.42±0.02 | 1.51±0.06 | 1.45±0.07 |
si-CircBACH1+anti- miR-140-5p组 | 0.72±0.04c | 1.21±0.05c | 1.17±0.05c |
F | 182.493 | 89.791 | 67.222 |
[1] | WALLINGTON-BEDDOE C T, MYNOTT R L. Prognostic and predictive biomarker developments in multiple myeloma[J]. J Hematol Oncol, 2021, 14(1):151. doi:10.1186/s13045-021-01162-7. |
[2] | CHEN J, ZAAL E A, BERKERS C R, et al. Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation[J]. Cells, 2021, 10(9):2287. doi:10.3390/cell10092287. |
[3] | SANTONI G, AMANTINI C, MAGGI F, et al. The mucolipin TRPML2 channel enhances the sensitivity of multiple myeloma cell lines to ibrutinib and/or bortezomib treatment[J]. Biomolecules, 2022, 12(1):107. doi:10.3390/biom12010107. |
[4] | MAHAJAN M, SITASAWAD S. miR-140-5p attenuates hypoxia-induced breast cancer progression by targeting Nrf2/HO-1 axis in a keap1-independent mechanism[J]. Cells, 2021, 11(1):12. doi:10.3390/cell11010012. |
[5] | LIU M, LIU H, ZHOU J, et al. miR-140-5p inhibits the proliferation of multiple myeloma cells by targeting VEGFA[J]. Mol Med Rep, 2021, 23(1):53. doi:10.3892/mmr.2020.11691. |
[6] | LU D, YANG C, ZHANG Z, et al. Knockdown of Linc00515 inhibits multiple myeloma autophagy and chemoresistance by upregulating miR-140-5p and downregulating ATG14[J]. Cell Physiol Biochem, 2018, 48(6):2517-2527. doi:10.1159/000492690. |
[7] | FARUQ O, ZHAO D, SHRESTHA M, et al. Targeting an MDM2/MYC axis to overcome drug resistance in multiple myeloma[J]. Cancers(Basel), 2022, 14(6):1592. doi:10.3390/cancers14061592. |
[8] | WANG Z, ZHANG S, ZHAO Y, et al. MicroRNA-140-3p alleviates intervertebral disc degeneration via KLF5/N-cadherin/MDM2/Slug axis[J]. RNA Biol, 2021, 18(12):2247-2260. doi:10.1080/15476286.2021.1898176. |
[9] | XU L, YAO Y, LU T, et al. miR-451a targeting IL-6R activates JAK2/STAT3 pathway, thus regulates proliferation and apoptosis of multiple myeloma cells[J]. J Musculoskelet Neuronal Interact, 2022, 22(2):251-260. |
[10] | MANNINO F, PALLIO G, CORSARO R, et al. Beta-caryophyllene exhibits anti-proliferative effects through apoptosis induction and cell cycle modulation in multiple myeloma cells[J]. Cancers(Basel), 2021, 13(22):5741. doi:10.3390/cancers13225741. |
[11] | LIU D, WANG Y, LI H, et al. Circular RNA circ-CCT3 promotes bortezomib resistance in multiple myeloma via modulating miR-223-3p/BRD4 axis[J]. Anticancer Drugs, 2022, 33(1):e145-e154. doi:10.1097/CAD.0000000000001166. |
[12] | LIU X, TANG H, LIU J, et al. hsa_circRNA_101237:A novel diagnostic and prognostic biomarker and potential therapeutic target for multiple myeloma[J]. Cancer Manag Res, 2020, 12:2109-2118. doi:10.2147/CMAR.S241089. |
[13] | MA H, SHEN L, YANG H, et al. Circular RNA circPSAP functions as an efficient miR-331-3p sponge to regulate proliferation,apoptosis and bortezomib sensitivity of human multiple myeloma cells by upregulating HDAC4[J]. J Pharmacol Sci, 2022, 149(1):27-36. doi:10.1016/j.jphs.2022.01.013. |
[14] | LI J, TANG Q, DONG W, et al. CircBACH1/let-7a-5p axis enhances the proliferation and metastasis of colorectal cancer by upregulating CREB5 expression[J]. J Gastrointest Oncol, 2020, 11(6):1186-1199. doi:10.21037/jgo-20-498. |
[15] | XUE L, JIA T, ZHU Y, et al. Down-regulation of circ_0058058 suppresses proliferation, angiogenesis and metastasis in multiple myeloma through miR-338-3p/ATG14 pathway[J]. J Orthop Surg Res, 2021, 16(1):723. doi:10.1186/s13018-021-02867-8. |
[16] | WU H, LIU C, YANG Q, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4[J]. Autophagy, 2020, 16(4):683-697. doi:10.1080/15548627.2019.1635380. |
[17] | GLUCK W L, GOUNDER M M, FRANK R, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma[J]. Invest New Drugs, 2020, 38(3):831-843. doi:10.1007/s10637-019-00840-1. |
[18] | LI C, SU R, WANG X, et al. Discovery of the oncogenic MDM2,a direct binding target of berberine and a potential therapeutic,in multiple myeloma[J]. Funct Integr Genomics, 2022, 22(5):1031-1041. doi:10.1007/s10142-022-00880-6. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||